Impact of pneumococcal vaccination on the management of infants with fever according to vaccination rates;Impacto de la vacunación neumocócica en el manejo del lactante con fiebre, en relación al porcentaje de vacunación

Anales de Pediatria

Volumn 67, Issue 1, 2007, Pages 30-36

  Capape Zache S ^a   Luaces Cubells, C ^b   Garrido Romero, R ^b   Claret Teruel, G ^b   Fernandez Landaluce A ^a   Benito Fernandez J ^a  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Febrile infants; Fever without source; Pediatric emergency department; Pneumococcal vaccination

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; PNEUMOCOCCUS CONJUGATE VACCINE 7; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD CELL COUNT; BLOOD CULTURE; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; HEALTH SURVEY; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; HYPOTHESIS; INFANT; MAJOR CLINICAL STUDY; PATIENT CARE; PEDIATRICIAN; PRESCHOOL CHILD; PYREXIA IDIOPATHICA; QUESTIONNAIRE; REPEATED DRUG DOSE; STATISTICAL ANALYSIS;

EID: 34547622290     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13108077     Document Type: Article

References (19)

1. Grupo de Trabajo sobre el Niño Febril. Sociedad Española de Urgencias de Pediatría. El niño febril. Resultados de un estudio multicéntrico. An Esp Pediatr. 2001;55:5-10.
2. a ed. Madrid: Ergón; 2006. p. 184-94.
3. Kuppermann N. Occult bacteremia in young febrile children. Pediatr Clin North Am. 1999;46:1073-109.
4. Kuppermann N, Fleisher GR, Jaffe L. Predictors of occult pneumococcal bacteriemia in young febrile children. Ann Emerg Med. 1999;31:679-87.
5. Mintegi S, González M, Pérez A, Pijoán JI, Capapé S, Benito J. Lactante de 3-24 meses con fiebre sin foco en urgencias: características, tratamiento y evolución posterior. An Pediatr (Barc). 2005;62:522-8.
6. Resumen de características del producto: Prevenar, suspensión para inyección. Vacuna neumocócica sacarídica conjugada, adsorbida. Louvain-la-Neuve: Wyeth Lederle Vaccines, S.A. 2 de febrero de 2001.
7. Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-9.
8. Stoll ML, Rubin LG. Incidence of occult bacteriemia among highly febrile young children in the era of the pneumococcal conjugate vaccine. A study from a Children's hospital emergency department and Urgent care center. Arch Pediatr Adolesc Med. 2004;158:671-5.
9. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46.
10. Black S, Shinefield H, Fireman B. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children: Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis. J 2000;19:187-95.
11. Nigrovic LE, Malley R. Evaluation of the febrile child 3 to 36 months old in the era of pneumococcal conjugate vaccine: focus on occult bacteremia. Clin Ped Emerg Med. 2004;5:13-9.
12. Gabriel ME, Aiuto L, Kohn N, Barone SR. Management of febrile children in the conjugate pneumococcal vaccine era. Clin Pediatr. 2004;43:75-82.
13. Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-74.
14. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54:893-7.
15. Klein JO. Management of pediatric pneumococcal diseases in the era of the pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2002;21:582-4.
16. Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of conjugate pneumococcal vaccine: A cost-effectiveness analysis. Pediatrics. 2001;108:835-44.
17. Isaacman DJ, Kaminer K, Veligeti H. Comparative practice patterns of emergency medicine physicians and pediatric emergency medicine physicians managing fever in young children. Pediatrics. 2001;108:354-8.
18. Mintegi S, Benito J, González M, Astobiza E, Sánchez J, Santiago M. Impact of the Pneumococcal Conjugate Vaccine in the Management of Highly Febrile Children Aged 6 to 24 Months in an Emergency Department. Pediatr Emerg Care. 2006;22:566-9.
19. Asociación Española de Pediatría. Disponible en: http://www.vacunasaep.org